| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| MAZEMaze Therapeutics, Inc. | 1.92B | 39.81 | 511.70 | 31.18% | -33.24% | 3.91% | 0.14 | |
| GNFTGenfit S.A. | 313.52M | 6.27 | 209 | 134.56% | -14.12% | -31.42% | 4.54% | 0.90 |
| GYREGyre Therapeutics, Inc. | 741.77M | 7.70 | 154 | -6.78% | 6.2% | 4.84% | 0.02 | |
| TVRDTvardi Therapeutics, Inc. | 42.31M | 4.51 | -0.10 | -65.96% | -317.54% | -63.46% | ||
| UNCYUnicycive Therapeutics, Inc. | 134.75M | 6.27 | -1.12 | -100% | -89.15% | 0.10 | ||
| GLTOGalecto, Inc. | 38.32M | 23.95 | -1.29 | -237.68% | 0.00 | |||
| IVAInventiva S.A. | 1.17B | 6.12 | -1.73 | -47.37% | -13.75% | |||
| AKBAAkebia Therapeutics, Inc. | 355.59M | 1.34 | -4.06 | -17.7% | -7.07% | -38.24% |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 180.83M | 179.58M | 125.67M | 212.96M | 256.58M | 176.32M | 235.31M | 140.73M | 46.8M | 29.62M |
| Revenue Growth % | 0.31% | -0.01% | -0.3% | 0.69% | 0.2% | -0.31% | 0.33% | -0.4% | -0.67% | -0.37% |
| Cost of Goods Sold | 214.09M | 187.21M | 196.52M | 235.84M | 1.15M | 8.87M | 449.19M | 20.28M | 3.96M | 15.56M |
| COGS % of Revenue | 1.18% | 1.04% | 1.56% | 1.11% | 0% | 0.05% | 1.91% | 0.14% | 0.08% | 0.53% |
| Gross Profit | -33.26M | -7.63M | -70.85M | -22.88M | 255.43M | 167.45M | -213.88M | 120.45M | 42.84M | 14.06M |
| Gross Margin % | -0.18% | -0.04% | -0.56% | -0.11% | 1% | 0.95% | -0.91% | 0.86% | 0.92% | 0.47% |
| Gross Profit Growth % | -1.52% | 0.77% | -8.29% | 0.68% | 12.16% | -0.34% | -2.28% | 1.56% | -0.64% | -0.67% |
| Operating Expenses | 258.45M | 233.23M | 248.28M | 299.65M | 344.74M | 359.33M | 74.65M | 421.48M | 365.56M | 164.48M |
| OpEx % of Revenue | 1.43% | 1.3% | 1.98% | 1.41% | 1.34% | 2.04% | 0.32% | 2.99% | 7.81% | 5.55% |
| Selling, General & Admin | 44.36M | 46.02M | 51.76M | 63.81M | 135.48M | 106.41M | 0 | 124.69M | 86.48M | 49.33M |
| SG&A % of Revenue | 0.25% | 0.26% | 0.41% | 0.3% | 0.53% | 0.6% | - | 0.89% | 1.85% | 1.67% |
| Research & Development | 214.09M | 187.21M | 196.52M | 235.84M | 209.26M | 252.92M | 387.04M | 296.79M | 266.47M | 95.69M |
| R&D % of Revenue | 1.18% | 1.04% | 1.56% | 1.11% | 0.82% | 1.43% | 1.64% | 2.11% | 5.69% | 3.23% |
| Other Operating Expenses | 0 | 0 | 0 | 42.16M | 0 | 0 | -312.4M | 0 | 12.61M | 19.45M |
| Operating Income | -77.63M | -53.65M | -122.61M | -86.69M | -89.31M | -191.88M | -288.53M | -301.02M | -322.72M | -150.42M |
| Operating Margin % | -0.43% | -0.3% | -0.98% | -0.41% | -0.35% | -1.09% | -1.23% | -2.14% | -6.9% | -5.08% |
| Operating Income Growth % | -0.55% | 0.31% | -1.29% | 0.29% | -0.03% | -1.15% | -0.5% | -0.04% | -0.07% | 0.53% |
| EBITDA | -71.95M | -47.61M | -116.51M | -80.13M | -67.86M | -169.83M | -273.72M | -290.42M | -312.79M | -147.72M |
| EBITDA Margin % | -0.4% | -0.27% | -0.93% | -0.38% | -0.26% | -0.96% | -1.16% | -2.06% | -6.68% | -4.99% |
| EBITDA Growth % | -0.58% | 0.34% | -1.45% | 0.31% | 0.15% | -1.5% | -0.61% | -0.06% | -0.08% | 0.53% |
| D&A (Non-Cash Add-back) | 5.68M | 6.04M | 6.1M | 6.56M | 21.45M | 22.05M | 14.81M | 10.6M | 9.93M | 2.69M |
| EBIT | -74.5M | -51.03M | -110.85M | -75.13M | -73.77M | -186.33M | -348.53M | -293.43M | -315.13M | -145.12M |
| Net Interest Income | -7.91M | -8.1M | -3.27M | 577K | 12.67M | 3.15M | -1.07M | 6.16M | -501K | -2.95M |
| Interest Income | 3.12M | 2.63M | 6.43M | 11.57M | 15.55M | 5.55M | - | 7.6M | 7.59M | 5.3M |
| Interest Expense | 11.03M | 10.72M | 9.71M | 10.99M | 2.88M | 2.4M | 1.07M | 1.44M | 8.1M | 8.25M |
| Other Income/Expense | -7.91M | -8.1M | -3.27M | 577K | 12.67M | 2.95M | -1.15M | 7.73M | -501K | -2.95M |
| Pretax Income | -85.54M | -61.75M | -125.88M | -86.12M | -76.64M | -188.93M | -289.68M | -293.3M | -323.22M | -153.37M |
| Pretax Margin % | -0.47% | -0.34% | -1% | -0.4% | -0.3% | -1.07% | -1.23% | -2.08% | -6.91% | -5.18% |
| Income Tax | 242K | -71K | 321K | 304K | 328K | 360K | 347K | 358K | -252K | -269K |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 0.88% | 0.31% |
| Net Income | -85.78M | -61.68M | -126.2M | -86.42M | -76.97M | -189.29M | -290.02M | -293.65M | -284.23M | -47.58M |
| Net Margin % | -0.47% | -0.34% | -1% | -0.41% | -0.3% | -1.07% | -1.23% | -2.09% | -6.07% | -1.61% |
| Net Income Growth % | -0.44% | 0.28% | -1.05% | 0.32% | 0.11% | -1.46% | -0.53% | -0.01% | 0.03% | 0.83% |
| Net Income (Continuing) | -85.78M | -61.68M | -120.88M | -86.42M | -76.97M | -189.29M | -290.02M | -293.65M | -322.97M | -153.1M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 38.74M | 105.52M |
| Minority Interest | 19.27M | 19.27M | 19.27M | 19.27M | 19.27M | 19.27M | 19.97M | 19.97M | 41.97M | 41.97M |
| EPS (Diluted) | -1.42 | -0.98 | -1.73 | -1.03 | -0.89 | -2.11 | -3.15 | -3.15 | -2.92 | -0.48 |
| EPS Growth % | -0.37% | 0.31% | -0.77% | 0.4% | 0.14% | -1.37% | -0.49% | 0% | 0.07% | 0.84% |
| EPS (Basic) | -1.42 | -0.98 | -1.73 | -1.03 | -0.89 | -2.11 | -3.15 | -3.15 | -2.92 | -0.48 |
| Diluted Shares Outstanding | 60.34M | 62.74M | 72.99M | 84.06M | 86.63M | 89.85M | 92.35M | 93.58M | 97.3M | 100.04M |
| Basic Shares Outstanding | 60.34M | 62.74M | 72.99M | 84.06M | 86.63M | 89.85M | 92.35M | 93.58M | 97.3M | 100.04M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 200.56M | 266.52M | 748.97M | 690.01M | 702.49M | 755.11M | 474.06M | 492.83M | 331.56M | 196.51M |
| Cash & Short-Term Investments | 181.17M | 253.18M | 735.72M | 621.4M | 533.76M | 686.54M | 405.19M | 422.01M | 235.59M | 50.48M |
| Cash Only | 153.32M | 173.78M | 673.66M | 89.26M | 126.27M | 678.39M | 171.22M | 155.7M | 113.69M | 50.48M |
| Short-Term Investments | 27.85M | 79.4M | 62.06M | 532.14M | 407.49M | 8.14M | 233.97M | 266.31M | 121.9M | 0 |
| Accounts Receivable | 15.4M | 10.45M | 8.45M | 63.68M | 153.66M | 41.88M | 25.4M | 16.3M | 41.05M | 481K |
| Days Sales Outstanding | 31.09 | 21.24 | 24.55 | 109.15 | 218.6 | 86.7 | 39.4 | 42.27 | 320.16 | 5.93 |
| Inventory | 0 | 0 | 0 | 0 | 6.89M | 16.53M | 31.02M | 40.44M | 41.56M | 3.15M |
| Days Inventory Outstanding | - | - | - | - | 2.19K | 680.29 | 25.2 | 727.77 | 3.83K | 74 |
| Other Current Assets | 3.99M | 2.89M | 4.8M | 4.93M | 1.72M | 1.81M | 5.07M | 4.35M | 6.71M | 140.49M |
| Total Non-Current Assets | 270.01M | 203.04M | 149.68M | 190.58M | 154.91M | 71.73M | 299.76M | 117.26M | 91.97M | 18.02M |
| Property, Plant & Equipment | 129.02M | 123.66M | 129.48M | 127.2M | 82.34M | 63.25M | 119.39M | 100.5M | 81.37M | 97K |
| Fixed Asset Turnover | 1.40x | 1.45x | 0.97x | 1.67x | 3.12x | 2.79x | 1.97x | 1.40x | 0.58x | 305.37x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 131.72M | 71.01M | 10.51M | 55.82M | 61.12M | 2.97M | 171.62M | 9.41M | 5.29M | 0 |
| Other Non-Current Assets | 9.27M | 8.37M | 9.7M | 7.57M | 11.44M | 5.5M | 8.75M | 7.35M | 5.31M | 17.92M |
| Total Assets | 470.57M | 469.55M | 898.65M | 880.6M | 857.4M | 826.84M | 773.82M | 610.09M | 423.53M | 214.53M |
| Asset Turnover | 0.38x | 0.38x | 0.14x | 0.24x | 0.30x | 0.21x | 0.30x | 0.23x | 0.11x | 0.14x |
| Asset Growth % | -0.03% | -0% | 0.91% | -0.02% | -0.03% | -0.04% | -0.06% | -0.21% | -0.31% | -0.49% |
| Total Current Liabilities | 67.18M | 65.13M | 77.26M | 89.03M | 102.75M | 163.19M | 225.5M | 273.56M | 217.67M | 133.31M |
| Accounts Payable | 6.52M | 6.22M | 5.51M | 9.14M | 6.09M | 24.79M | 26.1M | 30.76M | 17.96M | 5.06M |
| Days Payables Outstanding | 11.12 | 12.13 | 10.23 | 14.14 | 1.94K | 1.02K | 21.21 | 553.58 | 1.65K | 118.78 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 983K | 0 | 0 | 0 | 40K | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 490K | 1000K | 1000K | 1000K | 1000K | 0 |
| Other Current Liabilities | 34.4M | 36.68M | 17.38M | 44.69M | 63.05M | 95.53M | 4.91M | 7.25M | 152.58M | 115.23M |
| Current Ratio | 2.99x | 4.09x | 9.69x | 7.75x | 6.84x | 4.63x | 2.10x | 1.80x | 1.52x | 1.47x |
| Quick Ratio | 2.99x | 4.09x | 9.69x | 7.75x | 6.77x | 4.53x | 1.96x | 1.65x | 1.33x | 1.45x |
| Cash Conversion Cycle | - | - | - | - | 472.86 | -253.19 | 43.4 | 216.46 | 2.49K | -38.85 |
| Total Non-Current Liabilities | 206.57M | 229.32M | 238.94M | 263.1M | 219.25M | 222.2M | 319.21M | 338M | 368.06M | 264.85M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 89.7M | 90.1M |
| Capital Lease Obligations | 97.04M | 97.35M | 97.76M | 97.16M | 38.55M | 26.24M | 88.78M | 79.59M | 66.64M | 70K |
| Deferred Tax Liabilities | 4.7M | 4.21M | 3.66M | 3.04M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 24.39M | 25.26M | 167.19M | 29.83M | 81.25M | 57.49M | 43.63M | 72.69M | 54.17M | 174.68M |
| Total Liabilities | 273.75M | 294.44M | 316.2M | 352.13M | 321.99M | 385.39M | 544.71M | 611.57M | 585.73M | 398.16M |
| Total Debt | 97.04M | 97.35M | 97.76M | 97.16M | 51.89M | 39.76M | 99.72M | 89.89M | 170.46M | 90.17M |
| Net Debt | -56.28M | -76.43M | -575.89M | 7.9M | -74.38M | -638.63M | -71.5M | -65.81M | 56.77M | 39.69M |
| Debt / Equity | 0.49x | 0.56x | 0.17x | 0.18x | 0.10x | 0.09x | 0.44x | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -7.04x | -5.00x | -12.63x | -7.89x | -31.05x | -79.88x | -268.40x | -209.05x | -39.87x | -18.24x |
| Total Equity | 196.82M | 175.11M | 582.45M | 528.47M | 535.41M | 441.45M | 229.11M | -1.48M | -162.2M | -183.63M |
| Equity Growth % | -0.18% | -0.11% | 2.33% | -0.09% | 0.01% | -0.18% | -0.48% | -1.01% | -108.59% | -0.13% |
| Book Value per Share | 3.26 | 2.79 | 7.98 | 6.29 | 6.18 | 4.91 | 2.48 | -0.02 | -1.67 | -1.84 |
| Total Shareholders' Equity | 177.55M | 155.84M | 563.18M | 509.2M | 516.13M | 422.18M | 209.15M | -21.45M | -204.17M | -225.6M |
| Common Stock | 620K | 637K | 825K | 854K | 877K | 914K | 929K | 942K | 988K | 1.01M |
| Retained Earnings | -408.06M | -469.74M | -595.95M | -715.83M | -784.72M | -974.01M | -1.26B | -1.56B | -1.84B | -1.89B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.65M | -960K | -1.79M | -2.28M | -747K | -4.5M | -4.16M | -5.72M | -6.88M | -5.73M |
| Minority Interest | 19.27M | 19.27M | 19.27M | 19.27M | 19.27M | 19.27M | 19.97M | 19.97M | 41.97M | 41.97M |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -18.57M | 7.11M | -66.51M | -76.14M | -78.7M | 81.6M | -82.23M | -145.93M | -315.02M | -138M |
| Operating CF Margin % | -0.1% | 0.04% | -0.53% | -0.36% | -0.31% | 0.46% | -0.35% | -1.04% | -6.73% | -4.66% |
| Operating CF Growth % | -1.83% | 1.38% | -10.36% | -0.14% | -0.03% | 2.04% | -2.01% | -0.77% | -1.16% | 0.56% |
| Net Income | -85.78M | -58.07M | -120.88M | -86.42M | -76.97M | -189.29M | -290.02M | -293.65M | -284.23M | -47.58M |
| Depreciation & Amortization | 5.68M | 6.04M | 6.1M | 6.56M | 21.45M | 22.05M | 14.81M | 10.6M | 9.93M | 2.69M |
| Stock-Based Compensation | 27.68M | 32.13M | 37.54M | 52.14M | 66.27M | 72.72M | 71.16M | 65.6M | 50.77M | 25.21M |
| Deferred Taxes | 0 | -211K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.89M | 2.69M | 1.71M | -30K | -3.8M | 1.5M | 61.74M | 1.09M | 28.2M | -868K |
| Working Capital Changes | 30.96M | 24.52M | 9.02M | -48.4M | -85.66M | 174.63M | 60.08M | 70.43M | -119.69M | -117.46M |
| Change in Receivables | -1.95M | 4.96M | 2M | -55.23M | 35.23M | -11.97M | 25.18M | 765K | 3.43M | -6.74M |
| Change in Inventory | 0 | 0 | 0 | 0 | -6.89M | -9.18M | -14.16M | -11M | -1.7M | 22.28M |
| Change in Payables | 1.97M | -298K | -714K | 3.63M | -3.05M | 17.73M | 805K | 5.91M | -15.51M | 14.51M |
| Cash from Investing | -5.87M | 6.62M | 69.87M | -522.12M | 120.02M | 452.49M | -426.97M | 89.12M | 153.66M | 125.99M |
| Capital Expenditures | -1.98M | -1.25M | -8.5M | -8.02M | -5.76M | -3.99M | -5.19M | -3.74M | -2.52M | -266K |
| CapEx % of Revenue | 0.01% | 0.01% | 0.07% | 0.04% | 0.02% | 0.02% | 0.02% | 0.03% | 0.05% | 0.01% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 2K | 0 | 5K | 184K | 7K | 0 | -25M | -34.99M | 0 | 0 |
| Cash from Financing | 12.35M | 6.74M | 496.47M | 13.88M | -4.3M | 13.34M | -563K | 46.78M | 122.75M | -255K |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.23M |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | -2.24M | -2.74M | -9.24M | -15.61M | -12.75M | -11.46M | -7.37M | 43.13M | 748K | 1.88M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -20.55M | 5.86M | -75.01M | -84.16M | -84.47M | 77.61M | -112.42M | -184.67M | -317.54M | -138.26M |
| FCF Margin % | -0.11% | 0.03% | -0.6% | -0.4% | -0.33% | 0.44% | -0.48% | -1.31% | -6.78% | -4.67% |
| FCF Growth % | -2.44% | 1.28% | -13.81% | -0.12% | -0% | 1.92% | -2.45% | -0.64% | -0.72% | 0.56% |
| FCF per Share | -0.34 | 0.09 | -1.03 | -1.00 | -0.97 | 0.86 | -1.22 | -1.97 | -3.26 | -1.38 |
| FCF Conversion (FCF/Net Income) | 0.22x | -0.12x | 0.53x | 0.88x | 1.02x | -0.43x | 0.28x | 0.50x | 1.11x | 2.90x |
| Interest Paid | 335K | 295K | 255K | 218K | 174K | 135K | 94K | 104K | 54K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -39.21% | -33.17% | -33.32% | -15.56% | -14.47% | -38.76% | -86.5% | -258.01% | - | - |
| Return on Invested Capital (ROIC) | -37.2% | -33.64% | -174.77% | -23.95% | -13.43% | -109.09% | -137.3% | -499.96% | - | - |
| Gross Margin | -18.39% | -4.25% | -56.38% | -10.74% | 99.55% | 94.97% | -90.89% | 85.59% | 91.53% | 47.47% |
| Net Margin | -47.44% | -34.35% | -100.43% | -40.58% | -30% | -107.36% | -123.25% | -208.66% | -607.29% | -160.63% |
| Debt / Equity | 0.49x | 0.56x | 0.17x | 0.18x | 0.10x | 0.09x | 0.44x | - | - | - |
| Interest Coverage | -7.04x | -5.00x | -12.63x | -7.89x | -31.05x | -79.88x | -268.40x | -209.05x | -39.87x | -18.24x |
| FCF Conversion | 0.22x | -0.12x | 0.53x | 0.88x | 1.02x | -0.43x | 0.28x | 0.50x | 1.11x | 2.90x |
| Revenue Growth | 31.41% | -0.69% | -30.02% | 69.46% | 20.48% | -31.28% | 33.46% | -40.19% | -66.74% | -36.71% |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Drug Product Revenue | - | - | - | - | - | 8.91M | 962K | 11.09M | 18.75M | 27.67M |
| Drug Product Revenue Growth | - | - | - | - | - | - | -89.20% | 1052.39% | 69.16% | 47.57% |
| Product | - | - | - | - | - | 89.03M | - | - | - | - |
| Product Growth | - | - | - | - | - | - | - | - | - | - |
| Europe | - | - | - | 112.92M | 132.4M | - | - | - | - | - |
| Europe Growth | - | - | - | - | 17.26% | - | - | - | - | - |
| JAPAN | - | - | - | 100M | 122.47M | - | - | - | - | - |
| JAPAN Growth | - | - | - | - | 22.47% | - | - | - | - | - |
| All Other | - | - | - | 40K | 1.7M | - | - | - | - | - |
| All Other Growth | - | - | - | - | 4155.00% | - | - | - | - | - |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | - | - | - | - | - | - | 46.12M | 12.52M | 12.96M | 26.11M |
| UNITED STATES Growth | - | - | - | - | - | - | - | -72.86% | 3.53% | 101.48% |
| Europe | 159.12M | 153.67M | 108.76M | 112.92M | 132.4M | 67.16M | 131.24M | 33.82M | 9.55M | 6.27M |
| Europe Growth | - | -3.43% | -29.23% | 3.82% | 17.26% | -49.27% | 95.42% | -74.23% | -71.77% | -34.34% |
| CHINA | - | - | - | - | - | 72.5M | 55.64M | 84.63M | 109.38M | 91K |
| CHINA Growth | - | - | - | - | - | - | -23.25% | 52.10% | 29.24% | -99.92% |
| JAPAN | 21.6M | 25.78M | 16.89M | 100M | 122.47M | 36.66M | 2.31M | 9.76M | 15.87M | -2.85M |
| JAPAN Growth | - | 19.36% | -34.50% | 492.25% | 22.47% | -70.07% | -93.71% | 323.60% | 62.51% | -117.99% |
| All Other | 109K | 130K | 24K | 40K | 1.7M | - | - | - | - | - |
| All Other Growth | - | 19.27% | -81.54% | 66.67% | 4155.00% | - | - | - | - | - |
FibroGen, Inc. (FGEN) reported $-118.1M in revenue for fiscal year 2024. This represents a 279% decrease from $65.9M in 2012.
FibroGen, Inc. (FGEN) saw revenue decline by 36.7% over the past year.
Yes, FibroGen, Inc. (FGEN) is profitable, generating $215.7M in net income for fiscal year 2024 (-160.6% net margin).
Yes, FibroGen, Inc. (FGEN) pays a dividend with a yield of 0.25%. This makes it attractive for income-focused investors.
FibroGen, Inc. (FGEN) had negative free cash flow of $17.1M in fiscal year 2024, likely due to heavy capital investments.